The Medicines Company acquires antibiotics maker Rempex Pharma

USA-based The Medicines Company (Nasdaq: MDCO) has acquired Rempex Pharmaceuticals, a company with multiple potential new therapies focused on multi-drug resistant gram-negative bacteria.

Clive Meanwell, chairman and chief executive of The Medicines Company, said: "Acute and intensive care hospitals around the world face rapid and increasing antibacterial resistance, especially to gram-negative pathogens. The assets of Rempex, particularly Carbavance, will allow us to intensify our efforts to save lives, alleviate suffering and contribute to the economics of healthcare by serving leading hospitals."

Staged financial terms could total $474 million